This month, the cancer center hosted a conference with medical physicists and leaders in cancer technology from around the world. Here's how it will impact Louisiana.

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung ...

Cleveland-based University Hospitals Seidman Cancer Center became one of the first facilities in the U.S. to offer adaptive ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR inhibitor. The report provides product descriptions, patent details, and ...

Discover the facts about throat cancer symptoms, prevention tips, and breakthrough treatments giving patients new hope for ...

The following is a summary of "Quality of life and toxicity in patients with pancreatic ductal adenocarcinoma treated with ...

FYARRO holds strong market potential, particularly in treating rare and aggressive cancers like PEComa, where treatment options are limited. As the first FDA-approved therapy for advanced PEComa ...

The use of ablative radiation therapy (A-RT) led to promising overall survival and effective local tumor control in patients ...